Sol-Gel Technologies (SLGL) Non-Current Assets (2016 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Non-Current Assets of $2.8 million for Q1 2026, down 23.96% year-over-year from $3.6 million in Q1 2025, and down 6.28% quarter-over-quarter from $2.9 million in Q4 2025.
Analysis
Sol-Gel Technologies (SLGL) Non-Current Assets (2016 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Non-Current Assets for 11 consecutive years, with $2.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 23.96% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $2.8 million (down 23.96% YoY), while the FY2025 annual figure was $2.9 million, down 35.27% from the prior year.
- Non-Current Assets slipped to $2.8 million in Q1 2026 per SLGL's latest filing, from $2.9 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $9.3 million in Q1 2022 and bottomed at $2.8 million in Q1 2026.
- Historically, Non-Current Assets has averaged $4.5 million across 5 years, with a median of $3.7 million in 2022.
- On a YoY basis, Non-Current Assets climbed as much as 75.06% in 2022 and fell as far as 70.43% in 2022.
- Sol-Gel Technologies' Non-Current Assets stood at $3.6 million in 2022, then climbed by 15.31% to $4.1 million in 2023, then grew by 10.46% to $4.6 million in 2024, then sank by 35.27% to $2.9 million in 2025, then fell by 6.28% to $2.8 million in 2026.
- Business Quant data shows SLGL's Non-Current Assets at $2.8 million in Q1 2026, $2.9 million in Q4 2025, and $2.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.15 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 294.93 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.96 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 18.06 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Sol-Gel Technologies | 194.01 Mn | 146.08 Mn | - | 2.68 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.68 Mn |
| Mar 31, 2026 | 2.76 Mn |
| Dec 31, 2025 | 2.95 Mn |
| Sep 30, 2025 | 2.94 Mn |
| Jun 30, 2025 | 3.05 Mn |
| Mar 31, 2025 | 3.63 Mn |
| Dec 31, 2024 | 4.55 Mn |
| Sep 30, 2024 | 5.03 Mn |
| Jun 30, 2024 | 3.72 Mn |
| Mar 31, 2024 | 3.90 Mn |
| Dec 31, 2023 | 4.12 Mn |
| Sep 30, 2023 | 4.39 Mn |
| Jun 30, 2023 | 3.51 Mn |
| Mar 31, 2023 | 8.36 Mn |
| Dec 31, 2022 | 3.57 Mn |
| Sep 30, 2022 | 3.73 Mn |
| Jun 30, 2022 | 6.51 Mn |
| Mar 31, 2022 | 9.34 Mn |
| Dec 31, 2021 | 12.08 Mn |
| Sep 30, 2021 | 4.68 Mn |